BioPharmX Presents at American Congress of Obstetr
Post# of 223
Posted On: 05/16/2016 8:52:41 AM
BioPharmX Presents at American Congress of Obstetricians and Gynecologists (ACOG) Suggesting Molecular Iodine May be Effective, Non-hormonal Treatment for FBC
Patients with fibrocystic breasts may see reduction in breast discomfort without adverse side-effects
MENLO PARK, Calif., May 16, 2016 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology and women's health markets, addressed a major ob-gyn meeting this weekend and encouraged the assessment of molecular iodine as a non-hormonal treatment for pain associated with fibrocystic breast condition (FBC) and a viable alternative to the current standard of care.
A presentation to the Annual Clinical and Scientific Meeting of the American Congress of Obstetricians and Gynecologists (ACOG) in Washington, D.C. discussed scientific literature that shows most women with FBC-related breast discomfort may experience a reduction in symptoms after taking molecular iodine.
Dr. Lee Shulman, chairman of BioPharmX's Women's Breast Health Medical Advisory Board, and AnnaMarie Daniels, executive vice president of regulatory and clinical affairs at the company, shared information about a multi-center study which BioPharmX is conducting to evaluate the safety, tolerability and efficacy of molecular iodine as a treatment for cyclic breast pain.
The company's existing molecular iodine product, Violet® iodine, is commercially available in the United States. The company is also currently conducting a Phase 4 multicenter clinical trial in women with moderate to severe FBC is designed to expand claims.
Title: "Molecular Iodine (I2) as a non-hormonal treatment for fibrocystic breast pain in premenopausal women"
Location: Washington Convention Center, room 146 A
Date: Sunday, May 15
Time: 10:00 a.m. Eastern Daylight Time
"The current standard of care for FBC-related breast pain treats the condition with hormones, lifestyle changes or analgesics. While hormones are helpful in reducing breast pain, they often result in adverse side effects," said Dr. Shulman, who heads Clinical Genetics in the Department of Obstetrics and Gynecology at Northwestern University's Feinberg School of Medicine in Chicago. "Our review of literature shows that adequate daily supplementation with molecular iodine can significantly improve the quality of life for women."
FBC affects at least 70 percent of premenopausal women. The condition occurs when repeated hormonal exposure accelerates cell division, often resulting in the formation of cysts, fibrous tissue and chronic inflammation.
ACOG's annual meeting attracts thousands of leading women's health experts to share the latest scientific information to benefit patients.
Patients with fibrocystic breasts may see reduction in breast discomfort without adverse side-effects
MENLO PARK, Calif., May 16, 2016 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology and women's health markets, addressed a major ob-gyn meeting this weekend and encouraged the assessment of molecular iodine as a non-hormonal treatment for pain associated with fibrocystic breast condition (FBC) and a viable alternative to the current standard of care.
A presentation to the Annual Clinical and Scientific Meeting of the American Congress of Obstetricians and Gynecologists (ACOG) in Washington, D.C. discussed scientific literature that shows most women with FBC-related breast discomfort may experience a reduction in symptoms after taking molecular iodine.
Dr. Lee Shulman, chairman of BioPharmX's Women's Breast Health Medical Advisory Board, and AnnaMarie Daniels, executive vice president of regulatory and clinical affairs at the company, shared information about a multi-center study which BioPharmX is conducting to evaluate the safety, tolerability and efficacy of molecular iodine as a treatment for cyclic breast pain.
The company's existing molecular iodine product, Violet® iodine, is commercially available in the United States. The company is also currently conducting a Phase 4 multicenter clinical trial in women with moderate to severe FBC is designed to expand claims.
Title: "Molecular Iodine (I2) as a non-hormonal treatment for fibrocystic breast pain in premenopausal women"
Location: Washington Convention Center, room 146 A
Date: Sunday, May 15
Time: 10:00 a.m. Eastern Daylight Time
"The current standard of care for FBC-related breast pain treats the condition with hormones, lifestyle changes or analgesics. While hormones are helpful in reducing breast pain, they often result in adverse side effects," said Dr. Shulman, who heads Clinical Genetics in the Department of Obstetrics and Gynecology at Northwestern University's Feinberg School of Medicine in Chicago. "Our review of literature shows that adequate daily supplementation with molecular iodine can significantly improve the quality of life for women."
FBC affects at least 70 percent of premenopausal women. The condition occurs when repeated hormonal exposure accelerates cell division, often resulting in the formation of cysts, fibrous tissue and chronic inflammation.
ACOG's annual meeting attracts thousands of leading women's health experts to share the latest scientific information to benefit patients.
(0)
(0)